title: Serum lipids and glucose abnormalities in HIV/AIDS patients on antiretroviral therapies.
abstract: BACKGROUND
  With the introduction of highly active antiretroviral therapy (HAART) the outlook of HIV/AIDS has changed from a killer disease to a treatable chronic infectious one. However HAART is associated with some metabolic disorders some of which are now being seen in people living with HIV/ AIDS (PLWHA) accessing care from our centre.
  
  
  OBJECTIVE
  To determine the prevalence and pattern of dyslipidaemia and dysglycaemia amongst Nigerian HIV/AIDS patients on HAART.
  
  
  METHODS
  PLWHA who were regular on ART for at least three months and had pre-treatment CD4+ count, fasting lipid and glucose profiles were grouped into two treatment regimens: protease inhibitor, (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI). Pre and post-exposure metabolic and non-metabolic variables were compared for each regimen as well as within regimen comparison of the differences between post exposure metabolic variables.
  
  
  RESULTS
  Three hundred and twenty-seven patients; [male = 134 (41%), female = 193 (59%)] met the study criteria in the two groups: PI = 94 (29%) and NNRTI = 233 (71%). The pretreatment metabolic changes in both groups (PI vs. NNRTI) were low HDL-C; 29 (31%) vs. 77 (33%), followed by hypertriglyceridaemia; 16 (17%) vs. 38 (16%) and hypercholesterolaemia; 6 (6%) vs. 10 (4%). After exposure to two different HAART regimens hypertriglyceridaemia and hypercholesterolaemia became more prevalent especially with Pi based therapy than NNRTI; 74 (79%) vs. 108 (54%) and 58 (51%) vs.72 (31%) respectively. These relative higher risks of a PI containing regimen to induce hypertriglyceridaemia and hypercholesterolaemia were about three times more than that of NNRTI, both risks were statistically significant; p = 0.0003 and p = 0.0001.
  
  
  CONCLUSIONS
  Low HDL-C, hypertriglyceridaemia and hypercholesterolaemia are common in untreated HIV/AIDS patients. HAART especially those including protease inhibitors worsens this dyslipidaemia.
authors: Department of Medicine, College of Health Sciences, University of Ilorin, PMB 1515, Ilorin, Nigeria. salkaz2000@yahoo.com
authors: A K
authors: AK
authors: Salami
authors: A A
authors: AA
authors: Akande
authors: A B
authors: AB
authors: Olokoba
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019380:Anti-HIV Agents / Q000009:adverse effects*; D008076:Cholesterol, HDL; D016001:Confidence Intervals; D004196:Disease Outbreaks; D050171:Dyslipidemias / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005947:Glucose / Q000378:metabolism*; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology / Q000209:etiology*; D015228:Hypertriglyceridemia / Q000453:epidemiology / Q000209:etiology; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D015995:Prevalence; D012306:Risk; D012307:Risk Factors; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D008076:Cholesterol, HDL; D008055:Lipids; D005947:Glucose